ADMA BIOLOGICS, INC. Proceeds from Short-term Debt
ADMA BIOLOGICS, INC. (ADMA) reported Proceeds from Short-term Debt of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2020-11-05
- ADMA BIOLOGICS, INC. proceeds from short-term debt for the quarter ending 2020-09-30 was $0.00.
- ADMA BIOLOGICS, INC. proceeds from short-term debt for the quarter ending 2019-09-30 was $0.00.
| Period end | Proceeds from Short-term Debt 3 month | Proceeds from Short-term Debt 6 month | Proceeds from Short-term Debt 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-05 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$30.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$30.00M 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |